Encompass Health price target raised to $95 from $85 at Raymond James

Raymond James analyst John Ransom raised the firm’s price target on Encompass Health to $95 from $85 and keeps a Strong Buy rating on the shares. Encompass Health’s Q1 results were better than expected and management raised its FY guidance, and though the guidance looks conservative, the company cited pre-opening costs and Q1 one-timers as reasons for the modest guidance raise, the analyst tells investors in a research note.